Adolescent depression remains a pressing public health concern, with up to 40% of affected youth failing to respond to first-line treatments like selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy (CBT) (Lewis et al., 2024). As traditional interventions leave critical gaps in care, repetitive transcranial magnetic stimulation (rTMS) has emerged as a non-invasive, neuromodulatory alternative with growing evidence of efficacy and safety in this vulnerable population. This article synthesizes key findings from leading clinical research to explore how rTMS is reshaping adolescent depression treatment—from biomarker-guided protocols to symptom-specific outcomes.
The Case for rTMS in Adolescent Depression
Adolescence is a period of dynamic neurodevelopment, marked by ongoing maturation of prefrontal-limbic circuits involved in emotion regulation (Oberman et al., 2021). For youth with major depressive disorder (MDD), this developmental window is often characterized by structural and functional brain differences: studies show reduced amygdala and caudal anterior cingulate cortex (ACC) volumes in adolescents with MDD and treatment-resistant depression (TRD) compared to healthy peers (Seewoo et al., 2022). These neurostructural abnormalities, coupled with high placebo response rates (24–60%) in adolescent depression trials (Oberman et al., 2021), highlight the need for targeted, developmentally informed interventions.
rTMS addresses these challenges by modulating dysfunctional neural networks via pulsed magnetic fields. A meta-analysis of 16 randomized sham-controlled trials (Tao et al., 2025) confirmed that active rTMS significantly reduces depressive symptom severity (SMD = –0.93, 95% CI = –1.31 to –0.55) with a rapid onset—benefits are detectable as early as week 2 (SMD = –0.66) and persist through week 4 (SMD = –1.28). The treatment also improves response rates (RR = 1.24) and remission rates (RR = 1.63), with only 10 patients needing treatment to achieve one additional remission (Tao et al., 2025). For TRD—a subgroup with particularly limited options—rTMS offers hope by reversing neurostructural deficits: active 10 Hz rTMS to the left dorsolateral prefrontal cortex (DLPFC) increases amygdala volume by 4% and left DLPFC volume by 0.4% in adolescents with TRD, correlating with symptom improvement (Seewoo et al., 2022).
Optimizing rTMS: Biomarkers, Parameters, and Symptom Targeting
One of the most exciting advances in rTMS research is the shift toward personalized, biomarker-guided treatment. A pivotal dose-finding study (Lewis et al., 2024) identified intracortical facilitation (ICF)—a measure of glutamatergic NMDA receptor activity—as a key predictor of response. Adolescents with low baseline ICF (≤1.5) experienced significantly greater symptom reduction with 1 Hz rTMS (CDRS-R score reduction: d = 1.321) compared to 10 Hz rTMS, while those with high ICF (>1.5) showed no frequency-specific differences. This finding challenges the adult-centric convention of defaulting to 10 Hz stimulation and underscores the need for youth-specific protocols (Lewis et al., 2024).
Stimulation parameters also play a critical role in outcomes. While high-frequency (10 Hz) rTMS targeting the left DLPFC remains common, low-frequency (1 Hz) stimulation of the left DLPFC is superior for low-ICF youth (Lewis et al., 2024), and bilateral protocols (left 10 Hz + right 1 Hz) show promise (Oberman et al., 2021). Novel modes like intermittent theta burst stimulation (iTBS) reduce treatment time to 3 minutes per session while maintaining efficacy for suicidal ideation and depressive mood (Zhao et al., 2023 as cited in Liu et al., 2025). Notably, rTMS exerts differential effects across symptom clusters: it most effectively improves “subjective mood symptoms” (depressed mood, suicidal ideation; Cohen’s d = 2.41) and least effectively improves somatic symptoms (Cohen’s d = 0.59) in adolescents (Liu et al., 2025). This specificity helps clinicians set realistic expectations and tailor complementary interventions.
Safety and Tolerability: A Key Advantage for Youth
Safety is paramount in adolescent mental health care, and rTMS delivers a favorable profile. The most common adverse events are mild, transient headaches (34%) and treatment-site pain (46%), with 10 Hz stimulation associated with slightly higher rates than 1 Hz (Lewis et al., 2024). Seizures are extremely rare (incidence ~0.62%) and linked to high stimulation intensity or concurrent medications (Krishnan et al., 2015 as cited in Oberman et al., 2021). Long-term studies show no cognitive deterioration, and only minimal weight gain in the 10 Hz group (Lewis et al., 2024). Importantly, rTMS avoids the risk of increased suicidality associated with some SSRIs in youth (Miller and Campo, 2021 as cited in Seewoo et al., 2022), making it a valuable option for high-risk cases.
Current Limitations and Future Directions
Despite its promise, rTMS research in adolescents faces key limitations. Many studies have small sample sizes, and long-term follow-up data are scarce (Tao et al., 2025). Standardization of stimulation parameters (frequency, dose, targeting) is lacking, and few trials focus on subgroups like younger adolescents (10–14 years) or those with comorbidities (Oberman et al., 2021). Additionally, the high placebo response rate in adolescent trials necessitates rigorous sham-controlled designs to isolate rTMS-specific effects (Croarkin et al., 2021 as cited in Tao et al., 2025).
Future research should prioritize large-scale, longitudinal trials to validate biomarker-guided protocols (e.g., ICF stratification) and optimize parameters for TRD (Lewis et al., 2024). Combining rTMS with CBT or pharmacotherapy may enhance outcomes, as adjunctive use is already supported by FDA clearance for adolescents aged 15+ (FDA, 2024 as cited in Tao et al., 2025). Advances in neuronavigation—using MRI to target individual brain networks—may further improve efficacy by ensuring precise stimulation of the DLPFC (Oberman et al., 2021).
Conclusion
Repetitive transcranial magnetic stimulation represents a paradigm shift in adolescent depression treatment, offering a safe, targeted alternative for youth who do not benefit from traditional interventions. From biomarker-guided frequency selection to symptom-specific improvements, rTMS leverages our growing understanding of adolescent neurodevelopment to deliver personalized care. While further research is needed to address current limitations, the evidence—including meta-analytic support for efficacy (Tao et al., 2025), neurostructural normalization (Seewoo et al., 2022), and favorable safety (Lewis et al., 2024)—positions rTMS as a cornerstone of future adolescent mental health care. For clinicians and families navigating the challenges of adolescent depression, rTMS offers a beacon of hope: a non-invasive tool that respects the unique biology of youth brains while delivering meaningful, lasting relief.
References
- Croarkin, P. E., Elmaadawi, A. Z., Aaronson, S. T., et al. (2021). Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial. Neuropsychopharmacology, 46(2), 462–469.
- Lewis, C. P., Nakonezny, P. A., Sonmez, A. I., et al. (2024). A dose-finding, biomarker validation, and effectiveness study of transcranial magnetic stimulation for adolescents with depression. J Am Acad Child Adolesc Psychiatry, 64(10), 1179–1191.
- Liu, W.-J., Chen, W.-L., & Chen, H.-S. (2025). Exploratory analysis of symptom-specific efficacy of transcranial magnetic stimulation in adolescent depression. World J Psychiatry, 15(12), 111580.
- Oberman, L. M., Hynd, M., Nielson, D. M., et al. (2021). Repetitive transcranial magnetic stimulation for adolescent major depressive disorder: a focus on neurodevelopment. Front Psychiatry, 12, 642847.
- Seewoo, B. J., Rodger, J., Demitrack, M. A., et al. (2022). Neurostructural differences in adolescents with treatment-resistant depression and treatment effects of transcranial magnetic stimulation. Int J Neuropsychopharmacol, 25(8), 619–630.
- Tao, Y.-J., Duan, X.-X., Liu, P., et al. (2025). Efficacy and safety of repetitive transcranial magnetic stimulation in youth with depression: a systematic review and meta-analysis of randomized sham-controlled trials. World J Pediatr, 21(12), 1258–1274.